2 completed, 1 recruiting. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Recruiting 1 |
Follow Acute Myeloid Leukemia (AML) Relapse: new trials by email Literature Review of Acute Myeloid Leukemia (AML) Relapse trials Research Report on Acute Myeloid Leukemia (AML) Relapse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined With Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation. NK cell - Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML) Relapse | Phase 1 | Recruiting | Peking University First Hospital | 12 | 2025-11-01 | 2026-08-05 |
| Association of Ex Vivo Drug Response ( EVDR) and Clinical Outcome in Acute Myeloid Leukaemia (EXCYTE-2) No Interventions - Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML) Relapse | Completed | Exscientia AI Limited | 91 | 2024-05-13 | 2025-08-26 | |
| Trial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation F16IL2, BI 836858 - Acute Myeloid Leukemia (AML) Relapse | Phase 1 | Completed | Philogen S.p.A. | 15 | 2016-12-02 | 2022-04-20 |
Leukemia, Myeloid, Acute (3) · Recurrence (3)
Disease Attributes (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Leukemia (3) · Leukemia, Myeloid (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3)
BI 836858 (1)
Exscientia AI Limited (1) · Peking University First Hospital (1) · Philogen S.p.A. (1)
Germany (2) · Austria (1) · China (1) · Finland (1)
Nikolaus Krall, Dr. (1) · Yujun Dong, Docter (1)